ORAGENICS INC (OGEN) Fundamental Analysis & Valuation

NYSEARCA:OGEN • US6840236094

Current stock price

0.642 USD
+0.01 (+1.74%)
At close:
0.63 USD
-0.01 (-1.87%)
After Hours:

This OGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. OGEN Profitability Analysis

1.1 Basic Checks

  • In the past year OGEN has reported negative net income.
  • In the past year OGEN has reported a negative cash flow from operations.
  • In the past 5 years OGEN always reported negative net income.
  • OGEN had a negative operating cash flow in each of the past 5 years.
OGEN Yearly Net Income VS EBIT VS OCF VS FCFOGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • OGEN's Return On Assets of -97.76% is on the low side compared to the rest of the industry. OGEN is outperformed by 75.00% of its industry peers.
  • OGEN's Return On Equity of -118.85% is on the low side compared to the rest of the industry. OGEN is outperformed by 60.66% of its industry peers.
Industry RankSector Rank
ROA -97.76%
ROE -118.85%
ROIC N/A
ROA(3y)-410.45%
ROA(5y)-276.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OGEN Yearly ROA, ROE, ROICOGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K -2K 4K -4K -6K

1.3 Margins

  • OGEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OGEN Yearly Profit, Operating, Gross MarginsOGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10K -20K -30K -40K -50K

4

2. OGEN Health Analysis

2.1 Basic Checks

  • OGEN has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, OGEN has more shares outstanding
  • OGEN has a better debt/assets ratio than last year.
OGEN Yearly Shares OutstandingOGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
OGEN Yearly Total Debt VS Total AssetsOGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

2.2 Solvency

  • Based on the Altman-Z score of -32.66, we must say that OGEN is in the distress zone and has some risk of bankruptcy.
  • OGEN's Altman-Z score of -32.66 is on the low side compared to the rest of the industry. OGEN is outperformed by 89.92% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that OGEN is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.03, OGEN is in line with its industry, outperforming 43.02% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -32.66
ROIC/WACCN/A
WACCN/A
OGEN Yearly LT Debt VS Equity VS FCFOGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

  • OGEN has a Current Ratio of 5.64. This indicates that OGEN is financially healthy and has no problem in meeting its short term obligations.
  • OGEN has a Current ratio of 5.64. This is comparable to the rest of the industry: OGEN outperforms 59.69% of its industry peers.
  • A Quick Ratio of 5.64 indicates that OGEN has no problem at all paying its short term obligations.
  • OGEN has a better Quick ratio (5.64) than 60.27% of its industry peers.
Industry RankSector Rank
Current Ratio 5.64
Quick Ratio 5.64
OGEN Yearly Current Assets VS Current LiabilitesOGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

1

3. OGEN Growth Analysis

3.1 Past

  • OGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.47%, which is quite impressive.
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • OGEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.23% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.21%
EPS Next 2Y20.31%
EPS Next 3Y14.14%
EPS Next 5Y24.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OGEN Yearly Revenue VS EstimatesOGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2028 500K 1M 1.5M 2M
OGEN Yearly EPS VS EstimatesOGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -200 -400 -600 -800 -1K

0

4. OGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • OGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year OGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OGEN Price Earnings VS Forward Price EarningsOGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OGEN Per share dataOGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

  • OGEN's earnings are expected to grow with 14.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.31%
EPS Next 3Y14.14%

0

5. OGEN Dividend Analysis

5.1 Amount

  • OGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

OGEN Fundamentals: All Metrics, Ratios and Statistics

ORAGENICS INC

NYSEARCA:OGEN (4/24/2026, 8:04:00 PM)

After market: 0.63 -0.01 (-1.87%)

0.642

+0.01 (+1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners7.53%
Inst Owner Change0%
Ins Owners0.11%
Ins Owner Change-0.06%
Market Cap2.79M
Revenue(TTM)N/A
Net Income(TTM)-9.84M
Analysts82.86
Price Target2.04 (217.76%)
Short Float %16.99%
Short Ratio2.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-4.56
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-2.13
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS0
BVpS1.91
TBVpS1.91
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -97.76%
ROE -118.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-410.45%
ROA(5y)-276.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.64
Quick Ratio 5.64
Altman-Z -32.66
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.6%
EPS Next Y9.21%
EPS Next 2Y20.31%
EPS Next 3Y14.14%
EPS Next 5Y24.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.09%
EBIT Next 3Y-15.92%
EBIT Next 5YN/A
FCF growth 1Y-7.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.55%
OCF growth 3YN/A
OCF growth 5YN/A

ORAGENICS INC / OGEN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ORAGENICS INC (OGEN) stock?

ChartMill assigns a fundamental rating of 1 / 10 to OGEN.


What is the valuation status of ORAGENICS INC (OGEN) stock?

ChartMill assigns a valuation rating of 0 / 10 to ORAGENICS INC (OGEN). This can be considered as Overvalued.


How profitable is ORAGENICS INC (OGEN) stock?

ORAGENICS INC (OGEN) has a profitability rating of 0 / 10.


How financially healthy is ORAGENICS INC?

The financial health rating of ORAGENICS INC (OGEN) is 4 / 10.